Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zomedica Pharmaceuticals Corp (ZOM)

Zomedica Pharmaceuticals Corp (ZOM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Zomedica Corp. Announces Transition to OTCQB Venture Market

Zomedica's ticker symbol will change to ZOMDF

ZOM : 0.0973 (-0.21%)
Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

ANN ARBOR, MI / ACCESS Newswire / February 26, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products...

ZOM : 0.0973 (-0.21%)
Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

Relocation to More Efficient Space Supports Growth While Reducing Overhead by Over $200,000 Annually

ZOM : 0.0973 (-0.21%)
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis

Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform

ZOM : 0.0973 (-0.21%)
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology

ZOM : 0.0973 (-0.21%)
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform

ZOM : 0.0973 (-0.21%)
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

Seasoned executive brings a broad skill set to Zomedica's leadership team

ZOM : 0.0973 (-0.21%)
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024

ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products...

ZOM : 0.0973 (-0.21%)
Zomedica, Inc. to Present at the LD Micro Main Event XVI

Presentation on Tuesday, October 3rd at 1:00 PM PTAnn Arbor, Michigan--(Newsfile Corp. - September 27, 2023) - Zomedica Corp. (NYSE American: ZOM) (the "Company") announced today that the Company is scheduled...

ZOM : 0.0973 (-0.21%)
Why Shares of Zomedica Were Zooming Monday

Investors bought back into the stock after it fell to its lowest point in two months.

ZOM : 0.0973 (-0.21%)

Barchart Exclusives

Archer Aviation Is Bringing Its Flying Cars to Saudi Arabia. Is ACHR Stock a Buy Here?
Should you consider buying Archer Aviation’s stock as it gears up to bring its air-taxis to Saudi Arabia? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar